Charlotte Strandgren

Artiklar

Article: CELL DEATH & DISEASE. 2022;13(11):997

Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine

Palomar-Siles M; Heldin A; Zhang M; Strandgren C; Yurevych V; van Dinter JT; Engels SAG; Hofman DA; Ohlin S; Meineke B; Bykov VJN; van Heesch S; Wiman KG
Article: SCIENTIFIC REPORTS. 2018;8(1):15368

Expression of the Hutchinson-Gilford Progeria Mutation Leads to Aberrant Dentin Formation

Choi H; Kim T-H; Jeong J-K; Strandgren C; Eriksson M; Cho E-S
Article: FASEB JOURNAL. 2015;29(8):3193-3205

Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects

Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
Article: HUMAN MOLECULAR GENETICS. 2015;24(5):1305-1321

Expression of progerin in aging mouse brains reveals structural nuclear abnormalities without detectible significant alterations in gene expression, hippocampal stem cells or behavior

Baek J-H; Schmidt E; Viceconte N; Strandgren C; Pernold K; Richard TJC; Van Leeuwen FW; Dantuma NP; Damberg P; Hultenby K; Ulfhake B; Mugnaini E; Rozell B; Eriksson M

Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2024;21(2):106-120

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval A; Strandgren C; Heldin A; Palomar-Siles M; Wiman KG
Review: BIOCHEMICAL SOCIETY TRANSACTIONS. 2017;45(6):1279-1293

Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome

Strandgren C; Revechon G; Sola-Carvajal A; Eriksson M

Medicine Doktorsexamen, Institutionen för biovetenskaper och näringslära, Karolinska Institutet, 2017